Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289271 | 0.93 | SCN9A (0.72) | SCN9AALDH1A1 | |
| SCHEMBL10289026 | 0.89 | SCN9A (0.60) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL328294 | 0.88 | SCN9A (0.65) | SCN9A | |
| SCHEMBL328268 | 0.88 | SCN9A (0.61) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL328160 | 0.87 | SCN9A (0.60) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10289188 | 0.87 | SCN9A (0.55) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL280937 | 0.86 | SCN9A (0.86) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10289485 | 0.84 | SCN9A (0.51) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL10289199 | 0.84 | SCN9A (0.58) | SCN9AALDH1A1 | |
| SCHEMBL10288983 | 0.84 | SCN9A (0.52) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |